HC-BP-Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a de�ned time period Biogen does not comment on con�dential legal matters HC-BP-240b.3 Percentage change in: (1) list price and (2) net price of product with largest increase compared to previous year We regularly review our pricing strategy and prioritize patient access to our therapies.